GNH USA

Europe — EMA

Imukin (Recombinant Human Interferon Gamma 1b)

GNH USA supplies Imukin (Interferon gamma-1b), a cytokine immunomodulator for chronic granulomatous disease and severe malignant osteopetrosis.

Recombinant Human Interferon Gamma 1b

Request sourcing

1
Pack/s

What is Recombinant Human Interferon Gamma 1b?

Interferon gamma-1b, the active ingredient in Imukin, is a cytokine presented as a sterile solution for subcutaneous use. It modulates immune responses and is indicated for specific rare immunodeficiency and bone disorders in pediatric and adult patients.

GNH USA supplies Imukin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

What is Recombinant Human Interferon Gamma 1b used for?

Imukin is a recombinant cytokine used to treat disorders that involve defective immune activation or abnormal bone marrow function.

Chronic granulomatous disease (CGD): reduces the frequency and severity of bacterial and fungal infections in patients with defective NADPH‑oxidase activity. Severe malignant osteopetrosis (MOP): stimulates osteoclast development and improves hematopoiesis, helping to alleviate bone marrow failure in affected children. Autosomal recessive IFN‑γ receptor deficiency (investigational): aims to restore immune signaling pathways in patients with genetic receptor defects.

What are the side effects of Recombinant Human Interferon Gamma 1b?

Common Side Effects: - Flu‑like symptoms such as fever, chills, and muscle aches. - Injection‑site reactions including redness, swelling, or pain. - Headache and fatigue. - Nausea or mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angioedema). - Autoimmune hepatitis or elevated liver enzymes. - Hematologic abnormalities such as neutropenia or anemia. - Pulmonary edema or respiratory distress. - Significant depression or mood changes.

What precautions apply to Recombinant Human Interferon Gamma 1b?

Imukin requires careful monitoring due to its immunomodulatory activity. - Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown effects; consider discontinuation or monitor infant. - Renal impairment: adjust monitoring of renal function and drug levels. - Hepatic impairment: assess liver enzymes regularly. - Autoimmune disorders: evaluate risk of disease exacerbation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Recombinant Human Interferon Gamma 1b interact with?

Interferon gamma‑1b may interact with several agents that affect immune function or blood parameters.

Major Interactions (Avoid): - Live vaccines: may reduce vaccine efficacy; avoid concurrent administration. - High‑dose corticosteroids or other potent immunosuppressants: can blunt therapeutic response. - Antiviral agents such as ribavirin: potential additive toxicity.

Moderate Interactions (Monitor Closely): - Cytotoxic chemotherapy: monitor complete blood counts for additive myelosuppression. - Anticoagulants (e.g., warfarin): observe INR for possible changes. - Other biologic immunomodulators: assess for overlapping immune effects.

Frequently asked questions

What conditions is Imukin used to treat?+
Imukin (interferon gamma‑1b) is approved for chronic granulomatous disease, a rare immunodeficiency that leads to recurrent infections, and for severe malignant osteopetrosis, a disorder of bone remodeling that causes bone marrow failure. It may also be studied in other immune‑deficient conditions under clinical investigation.
How does interferon gamma‑1b work in the body?+
Interferon gamma‑1b binds to the interferon‑γ receptor on immune cells, triggering the JAK‑STAT signaling pathway. This activation increases expression of genes that enhance macrophage killing ability, improve antigen presentation, and promote a Th1‑type immune response, thereby correcting functional deficits in host defense and supporting hematopoiesis.
What is the usual dose of Imukin?+
The dosage of Imukin is individualized by the prescribing clinician based on the specific indication, patient weight, and clinical response. Dosing regimens are established in the product labeling and should be followed exactly as directed by a qualified healthcare professional.
Is Imukin safe to use during pregnancy or breastfeeding?+
Safety data for Imukin in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss individual risk factors and consider alternative therapies when appropriate.
How do I order Imukin from GNH USA?+
To request Imukin, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.
How does Imukin compare with other immunomodulators?+
Imukin is a recombinant cytokine that specifically activates the interferon‑γ pathway, whereas many other immunomodulators, such as interleukin‑2 or monoclonal antibodies, target different receptors or cytokines. This distinct mechanism makes Imukin particularly effective for conditions like CGD and osteopetrosis, where enhancing macrophage function is essential.
What are the storage requirements for Imukin?+
Imukin must be stored refrigerated between 2 °C and 8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain during transport is critical to preserve product stability.
How is Imukin administered?+
Imukin is supplied as a sterile solution for subcutaneous injection. The injection is typically given by a healthcare professional or trained caregiver, following aseptic technique. The injection site is rotated to minimize local irritation, and patients are observed for any immediate reactions.
What are the most serious risks associated with Imukin?+
Serious risks include severe allergic reactions such as anaphylaxis, autoimmune hepatitis, significant hematologic abnormalities like neutropenia, and pulmonary complications such as edema. Patients should be monitored closely for these events, and any signs of severe reaction require immediate medical attention.
Who should not receive Imukin?+
Imukin is contraindicated in individuals with known hypersensitivity to interferon gamma‑1b or any excipients in the formulation. Caution is advised for patients with uncontrolled autoimmune disease, severe hepatic impairment, or those receiving live vaccines. The prescribing clinician must evaluate each patient’s medical history before initiating therapy.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Recombinant Human Interferon Gamma 1b
Route
Subcutaneous Use
Manufacturer
Clinigen Healthcare B.V.
Origin
EU

Related products

Immukin

Immukin

Recombinant Human Interferon Gamma 1b

Clinigen Healthcare Ltd
EU
Immukine

Immukine

Recombinant Human Interferon Gamma 1b

Clinigen Healthcare B.V.
EU
Imukin

Imukin

Recombinant Human Interferon Gamma 1b

Clinigen Healthcare B.V.
EU
Imukin

Imukin

Recombinant Human Interferon Gamma 1b

Clinigen Healthcare B.V.
EU